Show simple item record

dc.contributor.authorRamberg, Cathrine
dc.contributor.authorHindberg, Kristian
dc.contributor.authorBiedermann, Joseph S.
dc.contributor.authorCannegieter, Suzanne C.
dc.contributor.authorvan der Meer, Felix J.
dc.contributor.authorSnir, Omri
dc.contributor.authorLeebeek, Frank W. G.
dc.contributor.authorKruip, Marieke J. H. A.
dc.contributor.authorHansen, John Bjarne
dc.contributor.authorLijfering, Willem M.
dc.date.accessioned2022-01-24T12:58:43Z
dc.date.available2022-01-24T12:58:43Z
dc.date.issued2021-12-25
dc.description.abstractBackground - Venous thromboembolism (VTE) is a frequent cardiovascular disease with severe complications, including recurrence and death. There is a great need for alternative prophylactic treatment options as anticoagulation is accompanied by increased bleeding risk. Statins are reported to reduce the risk of incident and recurrent VTE, but the mechanisms are elusive. Procoagulant phospholipids (PPL), and phosphatidylserine in particular, are crucial for efficient coagulation activation, but no studies have investigated the effect of statin treatment on plasma PPL activity.<p> <p>Objectives - To investigate the impact of rosuvastatin treatment on plasma PPL activity and levels of extracellular vesicles (EVs).<p> <p>Patients/Methods - Patients with a history of VTE (≥18 years) allowed to stop anticoagulant treatment were randomized to either 20 mg/day of rosuvastatin treatment or no treatment for 28 days in the Statins Reduce Thrombophilia (NCT01613794) trial. Plasma samples were collected at baseline and study end. PPL activity was measured in samples from 245 participants using a factor Xa-dependent clotting assay and EV levels by flow cytometry.<p> <p>Results - Rosuvastatin treatment yielded an overall 22% (95% confidence interval [CI] −38.2 to −5.8) reduction in PPL activity, and 37% (95% CI −62.9 to −11.2) reduction in PPL activity in participants with a history of pulmonary embolism. The effect of rosuvastatin on plasma PPL activity was not explained by changes in total cholesterol nor change in levels of total- or platelet-derived EVs.<p> <p>Conclusions - Rosuvastatin treatment caused a substantial decrease in plasma PPL activity, suggesting that a PPL-dependent attenuation of coagulation activation may contribute to a reduced VTE risk following statin treatment.en_US
dc.identifier.citationRamberg, Hindberg, Biedermann, Cannegieter, van der Meer, Snir, Leebeek, Kruip, Hansen, Lijfering. Rosuvastatin treatment decreases plasma procoagulant phospholipid activity after a VTE: A randomized controlled trial. Journal of Thrombosis and Haemostasis. 2021:1-11en_US
dc.identifier.cristinIDFRIDAID 1986776
dc.identifier.doi10.1111/jth.15626
dc.identifier.issn1538-7933
dc.identifier.issn1538-7836
dc.identifier.urihttps://hdl.handle.net/10037/23785
dc.language.isoengen_US
dc.publisherWileyen_US
dc.relation.journalJournal of Thrombosis and Haemostasis
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2021 The Author(s)en_US
dc.titleRosuvastatin treatment decreases plasma procoagulant phospholipid activity after a VTE: A randomized controlled trialen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record